Tag Archives: finance

Hot Investor Mandate: Europe-Based VC Firm Invests Through Seed to Growth-Stage Life Science Companies Across the Globe, With Preference for Therapeutics and Platform Technologies 

3 Sep

A venture capital firm with a major presence in Europe invests in life science companies through various funds. The firm targets seed, venture, and growth-stage investments in European companies but also considers North American and Asian opportunities. Initial investment size ranges from €500K – 10M, preferentially in the form of straight equity. The firm is capable of leading or co-investing in financing rounds; however, for U.S. deals, the firm prefers a local investor to lead unless it is a later-stage round (i.e., B, C, etc.) and the prior round was led by a U.S. investor. The firm has greater flexibility for European-based companies and typically leads these rounds. The firm is currently in investing mode, actively seeking opportunities, with the average investment ranging from €3–5M. 
 

The firm takes a true venture approach to investing and prioritizes breakthrough technologies with a strong IP position. Microbiome therapeutics and platforms are the primary interest, with willingness to invest as early as pre-clinical in this subsector. For other therapeutics, preferred phases of development are typically limited to pre-clinical investments into companies with a platform technology rather than those reliant on a single therapeutic asset. Medical technology and connected health companies are also evaluated, regardless of stage. 
 

The firm prefers to work with mature, experienced management teams but is open to all entrepreneurs. The firm will invest in pre-revenue as well as revenue-generating companies, with maximum revenues of €50M. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Investment Firm With Global Interests Seeks Novel Disruptive Therapeutics and Platform Technologies from Pre-Seed to Series A

3 Sep

A global venture capital investor builds, incubates, and invests in biotech companies. The firm invests from an evergreen fund and prefers to invest at company formation or seed stage, with the latest stage being Series A. Typical investments range from $1-5M, but larger tranched investments may be made in therapeutic opportunities. With offices across multiple global hubs, the firm invests worldwide. The firm can act as either a lead or a co-investor. 

The firm’s investment strategy focuses on disruptive therapeutics platform technologies and novel therapeutic modalities. 

The firm prefers to back teams with a strong track record but is also open to first-time entrepreneurs. At company formation, the firm not only provides funding for initial proof-of-concept studies, but also supports the assembly of the founding team and other essential business development activities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: USA-Based VC Firm Invests in Seed-Stage Life Science Companies, With a Focus on Companies in Longevity and AI

3 Sep

A venture capital firm founded in 2018 and based in the US actively invests in early-stage life science and healthcare companies with a focus on seed stage opportunities, investing up to $1M. The firm invests mostly in US, Europe, and Israel.  
 
The firm focuses on 2 areas: longevity and AI / future of healthcare. The firm is open to investing in therapeutics, medical devices, diagnostics, and digital health and will consider promising opportunities outside of these focus areas. 
 
The firm does not have specific management team requirements. The firm can lead or co-invest, and will typically seek board representation when leading investment rounds. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Seed Stage Investor Focuses on Pre-Clinical Drug Discovery Companies in CNS, Oncology, and Other Indications, Supporting Them for Clinical Readiness

3 Sep

A venture capital investor primarily makes angel investments in seed-stage companies and works hands-on with portfolio companies to facilitate regulatory approval and commercialization. Typical initial check size is in the $500–750K range, with tranche investments possible beyond this amount. The firm is open to global opportunities. 

The firm focuses on therapeutics companies in the early stages of drug discovery and development. Current areas of interest include CNS and neurodegenerative diseases, oncology, and pulmonary diseases pursued with novel approaches. While the firm works primarily with pre-clinical opportunities, it may consider other indications from time to time. 

The firm’s long-term strategy is to help companies progress toward Phase II readiness for pre-clinical assets. With broad expertise in regulatory and toxicology matters, the firm takes a hands-on approach to supporting portfolio companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Experience the Innovation at RESI Boston 2025! 

3 Sep

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Innovator’s Pitch Challenge (IPC) is a highlight of RESI Boston, bringing early-stage life science startups into the spotlight. Finalists will present across multiple sessions, showcasing breakthroughs in therapeutics, medical devices, diagnostics, digital health solutions, and R&D tools. Each pitch is delivered to a panel of active investors and industry experts who provide interactive questions and constructive feedback, while attendees also get a front-row seat to see the next wave of healthcare innovation.

RESI attendees are more than just spectators; they play an active role in the competition by “investing” their RESI cash in the companies they believe in most. This unique format allows the community to engage directly with the innovators, and the winners are revealed after the votes are tallied during the closing cocktail reception.

IPC participants also benefit from one-on-one partnering, exhibit space in the RESI Exhibition Hall, and the chance to compete for complimentary registration at future RESI conferences. Here are the presenting companies at RESI Boston September:

While applications to the IPC are now closed, you can still register for RESI Boston September 2025 to take part in everything the conference has to offer — from casting your vote in the IPC, to connecting with investors, attending panels and workshops, and making valuable new partnerships.

Tags: , , , , , ,

Corporate VC Panel: Venture and Innovation Arms Making Strategic Investments

3 Sep

By Joey Wong, Director of Investor Research, Hong Kong BD, LSN

Joey-New-Headshot

Many large corporations establish ventures or innovation arms to invest in and partner with life science and healthcare startups. Unlike traditional institutional VCs, corporate venture capital (CVC) groups bring unique strategies, goals, and ties to their parent organizations. Some CVCs focus closely on opportunities that align with the corporation’s core businesses, while others pursue innovation beyond existing portfolios, creating broader avenues for collaboration.

This 50-minute discussion will bring together leaders from corporate venture arms of global pharma, biotech, medtech, and healthcare corporations. Panelists will share how they evaluate early-stage opportunities, what distinguishes their investment criteria from institutional VCs, and how they balance strategic alignment with financial return. Startups will also gain valuable perspective on how to approach CVCs, what additional benefits they can expect beyond funding, and how relationships and collaboration may evolve post-investment.

For entrepreneurs seeking strategic partners, this session offers a chance to hear directly from active CVC investors about how they drive innovation, accelerate R&D, and bring transformative solutions to the market.

Andrew-Merken
Andrew Merken
Shareholder
Polsinelli PC
(Moderator) 		Komeil-Nasrollahi
Komeil Nasrollahi
Sr. Director Innovation & Venture Partnerships
Siemens Healthineers 		Claire-Leurent
Claire Leurent
Managing Director
AbbVie Ventures
Jeffrey-Moore
Jeffrey Moore
President
MP Healthcare Venture Management (MPH) 		Alex-de-Winter
Alex de Winter
VP of New Ventures
Danaher Corporation

Join us at RESI Boston this September to take part in this discussion and connect with investors across the life science and healthcare ecosystem.

Tags: , , , , ,

Hot Investor Mandate: Corporate Venture Arm of Global Manufacturing Company Makes Strategic Investments in Medical Devices, Diagnostics, and Biomanufacturing

26 Aug

A global manufacturing company operates across a wide range of industries, including analytical, medical, and industrial equipment. In recent years, the firm has placed a strong focus on healthcare, particularly in clinical diagnostics and biomanufacturing. 

A few years ago, the firm established a corporate venture capital (CVC) division to seek strategic partnerships with companies that possess cutting-edge technologies aligned with its business areas.  

The firm has invested in companies across the U.S., Canada, and Asia and is actively looking to expand its portfolio. While the CVC primarily targets investments in Seed to Series A rounds, it may also consider Series B opportunities. Typical check sizes range from $1 million to $5 million USD, though larger investments are possible for particularly promising technologies. 

Within healthcare, the firm is seeking opportunities in clinical diagnostics, medical devices, and biomanufacturing. The firm is open to not only hardware but also consumables and software solutions. 

To attract investment from the CVC, having a lead investor is desirable. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

← Older Entries
Newer Entries →